Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Ifezuntirgene inilparvovec by UniQure for Huntington Disease: Likelihood of Approval
Ifezuntirgene inilparvovec is under clinical development by UniQure and currently in Phase II for Huntington Disease. According to GlobalData, Phase...